Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity in Relapsed and Refractory Non-Hodgkin’s Lymphoma

類似資料

• The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
  著者:: Christian, Beth A., 等
  出版事項: (2015)
• Reduced Occurrence of Tumor Flare with Flavopiridol Followed by Combined Flavopiridol and Lenalidomidein Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
  著者:: Maddocks, Kami, 等
  出版事項: (2015)
• A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
  著者:: Ji, Jia, 等
  出版事項: (2013)
• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
  著者:: Byrd, John C., 等
  出版事項: (2007)
• A phase I trial of Flavopiridol in relapsed multiple myeloma
  著者:: Hofmeister, Craig C., 等
  出版事項: (2013)